Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds

Z Yao, Zuliang Yao, Yao Z, Shen X, Xun Shen, X Shen, Capodanno I, I Capodanno, Isabella Capodanno, Donnelly M, M Donnelly, Marcie J. Donnelly, Fenyk-Melody J, J Fenyk-Melody, Judy Fenyk‐Melody, Hausamann J, J Hausamann, Christian Nunes da Silva, Nunes C, C. Nunes, J Strauss, John R. Strauss, Strauss J, Vakerich K, K Vakerich, Ken Vakerich
Journal of investigative surgery : the official journal of the Academy of Surgical Research · 2005 · vol. 18(4) , pp. 177–183 · doi:10.1080/08941930591004412 · PMID:16126628 · W1965260226
Lab / animal OA: closed CC0 ⤵ 46 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study validated a rat endometriosis model by establishing that raloxifene at 10.0 mg/kg effectively reduced endometriotic implants, making it a reliable positive control for testing new SERM compounds.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Approximately 10% of women of reproductive age suffer from endometriosis, a potentially painful disease process and important cause of female infertility. Raloxifene, a commercially available SERM (selective estrogen receptor modulator) compound, used for the treatment of postmenopausal osteoporosis, has preclinically demonstrated its estrogen antagonist effect on uterine tissue in rats. There is potential that SERM compounds may become a viable treatment option for human endometriosis, although more investigation is needed. In this study, raloxifene was administered at various doses to determine the efficacy and an appropriate dose level for use as a positive control in a rat model of endometriosis. Prior to dose administration, all rats underwent a bilateral ovariectomy, autologous transplantation of uterine tissue onto the peritoneal surface of the abdominal wall, and implantation of a subcutaneous estrogen pellet (E2). Two separate postsurgical experiments were performed. In experiment 1, following a 4-wk recovery, the rats bearing implants were assigned to three groups: (1) removal of the E2 pellet and dosing vehicle only (n = 7); (2) E2 and vehicle (n = 6); and (3) E2 and raloxifene at 10.0 mg/kg (n = 6). In experiment 2, also following a 4-week recovery, the rats bearing implants were assigned to five groups (n = 8/group): (1) E2 and vehicle only; (2) E2 and raloxifene, 0.3 mg/kg/d; (3) E2 and raloxifene, 1.0 mg/kg/d; (4) E2 and raloxifene, 3.0 mg/kg/d; (5) E2 and raloxifene, 10.0 mg/kg/d. All rats were dosed orally BID for 14 d. At the end of the study, the implanted endometrium was remeasured and compared to the pretreatment measurement. The results from both studies demonstrated that Raloxifene at only one dose (10.0 mg/kg) displayed significant implant regression (p < .05). Subsequently, our rat endometriosis experimental model consistently uses the exogenous E2 pellet and raloxifene at 10 mg/kg, BID, as a positive control to help screen and compare novel SERM compounds.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Disease Models, Animal Disease Models, Animal Endometriosis Raloxifene Hydrochloride Rats, Sprague-Dawley Rats, Sprague-Dawley Selective Estrogen Receptor Modulators Animals Animals Endometriosis Endometriosis Endometriosis Endometrium Endometrium Endometrium Endometrium Female Female Organ Size Organ Size

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (9)

Cited by (47)

Source provenance

europepmc
last seen: 2026-10-16T06:09:50.462052+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:03:18.265172+00:00
License: CC0 · commercial use OK